AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19893121 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (Neupogen) administered systematically during antiviral therapy
Number of subjects: 64
Study 19893121 — intervention group
Group type: COMPARATOR
Intervention: Combination antiviral therapy (pegylated interferon alfa plus ribavirin) without Filgrastim
Number of subjects: 64
Study 17536485 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 9.05 mmol (220 mg) magnesium/d for 72 d
Number of subjects: 11
Study 17536485 — intervention group
Group type: COMPARATOR
Intervention: Basal diet with lactose placebo
Number of subjects: 11
Study 17536485 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium deprivation
Number of subjects: 11
Study 15449150 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 600 mg/day preoperatively for 7 consecutive days
Number of subjects: 30
Study 15449150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy or radiotherapy)
Number of subjects: 30
Study 11374748 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-construal activation (personal self-construals 'I')
Number of subjects: 0
Study 11374748 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-construal activation (social self-construals 'we')
Number of subjects: 0
Study 11374748 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-unrelated information processing styles (differentiation mind-set)
Number of subjects: 0
Study 11374748 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-unrelated information processing styles (integration mind-set)
Number of subjects: 0
Study 9684137 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated phosphatidyl-choline (PPC)
Number of subjects: 176
Study 9684137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 9684137 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged PPC therapy
Number of subjects: 176
Study 8113778 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer case management team
Number of subjects: 91
Study 8113778 — intervention group
Group type: COMPARATOR
Intervention: Nonconsumer case management team
Number of subjects: 91
Study 2541967 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated capsules (Nonoxynol-9)
Number of subjects: 96
Study 2541967 — intervention group
Group type: COMPARATOR
Intervention: Non-treated capsules (Nonoxynol-9)
Number of subjects: 96
Study 29607658 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of none of the conditions (mental illness, hazardous alcohol use, drug dependence)
Number of subjects: 106
Study 29607658 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of all three conditions (mental illness, hazardous alcohol use, drug dependence)
Number of subjects: 106
Study 27054712 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient empowerment training
Number of subjects: 0
Study 25654952 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) tonsillectomy
Number of subjects: 114
Study 25654952 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection (CD) tonsillectomy
Number of subjects: 114
Study 25654952 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RF and CD techniques
Number of subjects: 114
Study 23737387 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 0
Study 23737387 — intervention group
Group type: COMPARATOR
Intervention: Distraction intervention
Number of subjects: 0
Study 20009954 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials in stroke research
Number of subjects: 0
Study 18389499 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LH)
Number of subjects: 41
Study 18389499 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GH)
Number of subjects: 41
Study 16231766 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg x h(‐1) fentanyl and 4 mg x h(‐1) ketamine
Number of subjects: 50
Study 16231766 — intervention group
Group type: COMPARATOR
Intervention: 25 microg x h(‐1) fentanyl
Number of subjects: 50
Study 16231766 — intervention group
Group type: COMPARATOR
Intervention: 35 microg x h(‐1) subcutaneous fentanyl infusion
Number of subjects: 50
Study 16231766 — intervention group
Group type: COMPARATOR
Intervention: 50 microg x h(‐1) subcutaneous fentanyl infusion
Number of subjects: 50
Study 16231766 — intervention group
Group type: COMPARATOR
Intervention: 25 microg x h(‐1) fentanyl and 2 mg x h(‐1) ketamine
Number of subjects: 50
Study 12220322 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 29
Study 12220322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12220322 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (placebo add-on treatment)
Number of subjects: 29
Study 10197944 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric rating scale accompanied by an educational programme for nurses
Number of subjects: 0
Study 7551775 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright faces
Number of subjects: 126
Study 7551775 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted faces
Number of subjects: 126
Study 7551775 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright and inverted faces
Number of subjects: 126
Study 1969567 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (diuretics or beta-blockers)
Number of subjects: 37000
Study 7026258 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg i.v.)
Number of subjects: 0
Study 7026258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31493956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin-Augmented HIFU
Number of subjects: 60
Study 31493956 — intervention group
Group type: COMPARATOR
Intervention: HIFU (Control)
Number of subjects: 60
Study 31493956 — intervention group
Group type: COMPARATOR
Intervention: UAE (Control)
Number of subjects: 60
Study 28578427 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g glutamine administration
Number of subjects: 0
Study 28578427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25811813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ingestion
Number of subjects: 0
Study 25811813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25811813 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 23648352 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for elevated serum muscle enzymes in HP patients
Number of subjects: 41
Study 23648352 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum muscle enzymes in HP patients
Number of subjects: 41
Study 21849260 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 1000 mg/day
Number of subjects: 0
Study 21849260 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 1500 mg/day
Number of subjects: 0
Study 21849260 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate (higher dosages)
Number of subjects: 0
Study 21849260 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate (<1000 mg/day)
Number of subjects: 0
Study 21849260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19956159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer awareness measure (CAM)
Number of subjects: 1500
Study 17245623 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate plus hydroxyurea (500 mg twice a day)
Number of subjects: 39
Study 17245623 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate plus hydroxyurea
Number of subjects: 39
Study 15491247 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg of clonidine
Number of subjects: 14
Study 15491247 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg of clonidine
Number of subjects: 14
Study 15491247 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study 11191092 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel (150 microg orally daily) and testosterone pellets (2 x 200 mg per 12 weeks)
Number of subjects: 16
Study 11191092 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (150 microg orally daily) and testosterone pellets (2 x 200 mg per 12 weeks) with finasteride (5 mg orally daily)
Number of subjects: 16
Study 11191092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (control and FIN)
Number of subjects: 16
Study 9682338 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP/PRP-T combined in a dual-chamber syringe (D-Ch group, n = 239)
Number of subjects: 537
Study 9682338 — intervention group
Group type: COMPARATOR
Intervention: DTP@PRP-T combined in a single-chamber syringe (C-In group, n = 61)
Number of subjects: 537
Study 9682338 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP + PRP-T administered in separate injections (S-In group, n = 237)
Number of subjects: 537
Study 7982415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (46-52 mmol/18-20 h)
Number of subjects: 148
Study 7982415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium hydroxide (600 mg/day)
Number of subjects: 148
Study 7982415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium treatment)
Number of subjects: 148
Study 3422667 — intervention group
Group type: COMPARATOR
Intervention: Mixed-fluoride dentifrice (1,000 ppm F)
Number of subjects: 2509
Study 3422667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-fluoride dentifrice (2,500 ppm F)
Number of subjects: 2509
Study 3422667 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Na2PO3F dentifrice (1,000 ppm F)
Number of subjects: 2509
Study 29478953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoons with healthy eating messages
Number of subjects: 142
Study 29478953 — intervention group
Group type: COMPARATOR
Intervention: Cartoons with no reference to food (comparison group)
Number of subjects: 142
Study 26457893 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group music therapy (n = 62; 20 units of 40 minutes, 2×/week)
Number of subjects: 117
Study 26457893 — intervention group
Group type: COMPARATOR
Intervention: Recreational group singing (n = 55; 10 units of 90 minutes, 1×/week)
Number of subjects: 117
Study 26077620 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Cognitive Behavioral Therapy (T‐CBT)
Number of subjects: 325
Study 26077620 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-Face Cognitive Behavioral Therapy (FtF‐CBT)
Number of subjects: 325
Study 26077620 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy (CSE) scale
Number of subjects: 325
Study 26077620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CSE
Number of subjects: 325
Study 26077620 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support, physical functioning, and employment
Number of subjects: 325
Study 26077620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 325
Study 26077620 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment delivery method (T‐CBT vs FtF‐CBT)
Number of subjects: 325
Study 22795245 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission hyperglycemia (highest glucose tertile)
Number of subjects: 3405
Study 22795245 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission hyperglycemia (highest glucose tertile) in patients with diabetes
Number of subjects: 3405
Study 22795245 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission hyperglycemia (highest glucose tertile) in patients without diabetes
Number of subjects: 3405
Study 22795245 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hyperglycemia
Number of subjects: 3405
Study 22795245 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hyperglycemia in patients with diabetes
Number of subjects: 3405
Study 22795245 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hyperglycemia in patients without diabetes
Number of subjects: 3405
Study 21709518 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention (home visits and phone calls) for fathers (n = 19)
Number of subjects: 28
Study 21709518 — intervention group
Group type: COMPARATOR
Intervention: Control group (phone number of an experienced parent to call as needed) for fathers (n = 9)
Number of subjects: 28
Study 18353632 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent treatment protocols with higher cumulative doses or increased dose intensity of alkylators and epipodophyllotoxins and the use of G-CSF
Number of subjects: 237
Study 18353632 — intervention group
Group type: COMPARATOR
Intervention: Earlier treatment protocols
Number of subjects: 237
Study 18353632 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment for ESFT
Number of subjects: 237
Study 18353632 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary leukaemia (SL)
Number of subjects: 237
Study 18353632 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary solid tumours
Number of subjects: 237
Study 16850908 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine + Melatonin (CBZ+MEL)
Number of subjects: 22
Study 16850908 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate + Melatonin (VPA+MEL)
Number of subjects: 22
Study 12620695 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior antihypertensive treatment
Number of subjects: 960
Study 11137246 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hepatitis A and B vaccine (2 doses at month 0 and 6)
Number of subjects: 100
Study 11137246 — intervention group
Group type: COMPARATOR
Intervention: Twinrix (3 doses at month 0, 1, and 6)
Number of subjects: 100
Study 11137246 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hepatitis A and B vaccine
Number of subjects: 100
Study 11137246 — intervention group
Group type: COMPARATOR
Intervention: Twinrix
Number of subjects: 100
Study 11137246 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 100
Study 9196432 — intervention group
Group type: EXPERIMENTAL
Intervention: PRINS technique for detecting chromosome gains or losses in interphase nuclei
Number of subjects: 10
Study 9196432 — intervention group
Group type: COMPARATOR
Intervention: FISH analysis
Number of subjects: 10
Study 8482290 — intervention group
Group type: EXPERIMENTAL
Intervention: Long prednisone therapy (60 mg/m2 per 24 h for 6 weeks, followed by alternate day 40 mg/m2 per 48 h for 6 weeks)
Number of subjects: 71
Study 8482290 — intervention group
Group type: COMPARATOR
Intervention: Standard prednisone therapy (60 mg/m2 per 24 h for 4 weeks, followed by 40 mg/m2 per 48 h for 4 weeks)
Number of subjects: 71
Study 8482290 — intervention group
Group type: EXPERIMENTAL
Intervention: Long prednisone therapy
Number of subjects: 71
Study 8482290 — intervention group
Group type: COMPARATOR
Intervention: Standard prednisone therapy
Number of subjects: 71
Study 3434601 — intervention group
Group type: EXPERIMENTAL
Intervention: Models administration of three-dimensional constructional praxis tests
Number of subjects: 24
Study 3434601 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographs administration of three-dimensional constructional praxis tests
Number of subjects: 24
Study 3434601 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawings administration of three-dimensional constructional praxis tests
Number of subjects: 24
Study 29306481 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment + 25(OH)D3 supplementation
Number of subjects: 41
Study 29306481 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 41
Study 29306481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 25(OH)D levels ≤ 50 nmol/L
Number of subjects: 41
Study 29306481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 25(OH)D levels > 50 nmol/L
Number of subjects: 41
Study 26685099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose combined with NNS (group NS)
Number of subjects: 671
Study 26685099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose combined with swaddling (group SS)
Number of subjects: 671
Study 26685099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose combined with NNS and swaddling (group NSS)
Number of subjects: 671
Study 26685099 — intervention group
Group type: COMPARATOR
Intervention: Oral sucrose (routine care, group S)
Number of subjects: 671
Study 25639787 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-Colon Water Exchange (LWE)
Number of subjects: 300
Study 25639787 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Colon Water Exchange (WWE)
Number of subjects: 300
Study 25639787 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 300
Study 23733781 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparameter flow cytometry (MFC) assessment of minimal residual disease (MRD) after ASCT
Number of subjects: 378
Study 23733781 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance thalidomide
Number of subjects: 378
Study 23733781 — intervention group
Group type: COMPARATOR
Intervention: MRD assessment after induction therapy in non-intensive-pathway patients
Number of subjects: 378
Study 20956707 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal peer support (RPS)
Number of subjects: 244
Study 20956707 — intervention group
Group type: COMPARATOR
Intervention: Nurse care management (NCM)
Number of subjects: 244
Study 18350366 — intervention group
Group type: EXPERIMENTAL
Intervention: Information booklets provided to participants within 72 hours of the initial trauma.
Number of subjects: 103
Study 18350366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 103
Study 19641202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate at a dose of 2 mg/kg/day for 7 days
Number of subjects: 80
Study 19641202 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate at a dose of 4 mg/kg/day for 3 days followed by mefloquine at a total dose of 25 mg/kg
Number of subjects: 80
Study 19641202 — intervention group
Group type: COMPARATOR
Intervention: Artesunate monotherapy
Number of subjects: 80
Study 19641202 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-mefloquine therapy
Number of subjects: 80
Study 15774110 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst mode phaco power
Number of subjects: 178
Study 15774110 — intervention group
Group type: COMPARATOR
Intervention: Pulse mode phaco power
Number of subjects: 178
Study 15774110 — intervention group
Group type: COMPARATOR
Intervention: Continuous mode phaco power
Number of subjects: 178
Study 11167792 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD-HAM (high-dose AraC, mitoxantrone)
Number of subjects: 90
Study 11167792 — intervention group
Group type: COMPARATOR
Intervention: TAD-TAD (thioguanine, daunorubicin, cytosine arabinoside)
Number of subjects: 90
Study 9720995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exposure to hypoxia during exercise training (30 min x day(‐1) for 6 days)
Number of subjects: 13
Study 9720995 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 13
Study 9720995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exposure to hypoxia (with or without exercise training)
Number of subjects: 13
Study 9720995 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (intermittent exposure to hypoxia)
Number of subjects: 13
Study 8152203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 8 mg/kg bodyweight once daily
Number of subjects: 154
Study 8152203 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 20,000 I.E. /kg bodyweight t.i.d.
Number of subjects: 154
Study 8152203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 154
Study 8152203 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 154
Study 3048643 — intervention group
Group type: COMPARATOR
Intervention: DDP (100 mg/m2; day 1)
Number of subjects: 74
Study 3048643 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP + 5-fluorouracil (1 g/m2 continuous infusion for 5 days)
Number of subjects: 74
Study 3048643 — intervention group
Group type: COMPARATOR
Intervention: DDP
Number of subjects: 74
Study 3048643 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP + 5-fluorouracil
Number of subjects: 74
Study 31991298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index/high fat, high-calorie diet
Number of subjects: 44
Study 31991298 — intervention group
Group type: COMPARATOR
Intervention: High fat, high-calorie diet
Number of subjects: 44
Study 31325348 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education by telephone follow-up (4 times after discharge)
Number of subjects: 92
Study 31325348 — intervention group
Group type: COMPARATOR
Intervention: Control group (telephone follow-up once after discharge)
Number of subjects: 92
Study 28486643 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite self-management (WSM)
Number of subjects: 180
Study 28486643 — intervention group
Group type: COMPARATOR
Intervention: Intensive health monitoring (IM)
Number of subjects: 180
Study 26385357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise (60-minute class, twice weekly for 12 weeks)
Number of subjects: 53
Study 24373475 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel flight planning optimization application
Number of subjects: 839
Study 24373475 — intervention group
Group type: COMPARATOR
Intervention: Traditional planning methods (manual methods)
Number of subjects: 839
Study 23046006 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CP) mouth rinse, rinsed four times a day
Number of subjects: 52
Study 23046006 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CP) mouth rinse
Number of subjects: 52
Study 23046006 — intervention group
Group type: COMPARATOR
Intervention: Control group (not using CP mouth rinse)
Number of subjects: 52
Study 23046006 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (not using CP mouth rinse)
Number of subjects: 52
Study 19412946 — intervention group
Group type: EXPERIMENTAL
Intervention: CLE (37.7, 150, 200 mg)
Number of subjects: 17
Study 19412946 — intervention group
Group type: COMPARATOR
Intervention: CL-CR (50 and 200 mg)
Number of subjects: 17
Study 17460371 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg/day
Number of subjects: 42
Study 17460371 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg/day
Number of subjects: 42